Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

B0200000

Baclofen

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

(±)-Baclofen, (±)-β-(Aminomethyl)-4-chlorobenzenepropanoic acid, Lioresal

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H12ClNO2
Número de CAS:
1134-47-0
Peso molecular:
213.66
MDL number:
MFCD00055143
UNSPSC Code:
41116107
PubChem Substance ID:
329773100
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

baclofen

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

ClC1=CC=C(C(CN)CC(O)=O)C=C1

InChI

1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)

InChI key

KPYSYYIEGFHWSV-UHFFFAOYSA-N

Gene Information

human ... GABBR1(2550) , GABBR2(9568)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Baclofen EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

GABAB receptor agonist; skeletal muscle relaxant; antispastic agent.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

April Erwin et al.
Multiple sclerosis (Houndmills, Basingstoke, England), 17(5), 623-629 (2011-02-02)
The majority of patients with multiple sclerosis (MS) have symptoms of spasticity that increasingly impair function as the disease progresses. With appropriate treatment, however, quality of life can be improved. Oral antispasticity medications are useful in managing mild spasticity but
Amanda McIntyre et al.
The journal of spinal cord medicine, 37(1), 11-18 (2013-10-05)
To review the available evidence on the effectiveness of intrathecal baclofen in the treatment of spasticity in individuals with spinal cord injuries (SCIs) at least 6 months post-injury or diagnosis. A literature search of multiple databases (Pub Med, CINAHL, EMBASE)
Andrés P Varani et al.
Psychopharmacology, 231(15), 3031-3040 (2014-02-21)
Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence. The aim of the
Tamis W Pin et al.
Developmental medicine and child neurology, 53(10), 885-895 (2011-06-04)
Studies on the use of intrathecal baclofen (ITB) for ambulant adults with spasticity and/or dystonia of cerebral origin are scarce, and are even more limited for children and adolescents. This systematic review investigates the use of ITB to improve walking
Roberta Agabio et al.
European addiction research, 19(6), 325-345 (2013-06-19)
It has been reported that baclofen, a drug used in the treatment of spasticity, reduces the severity of withdrawal symptoms and substance use disorders (SUDs) for some psychoactive drugs. To evaluate the effectiveness and safety of baclofen in the treatment
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico